Processing

Please wait...

Settings

Settings

Goto Application

1. IN201947029719 - PHENYLDIFLUOROMETHYL-SUBSTITUTED PROLINEAMIDE COMPOUND

Office
India
Application Number 201947029719
Application Date 23.07.2019
Publication Number 201947029719
Publication Date 02.08.2019
Publication Kind A
IPC
C07D 207/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
04having no double bonds between ring members or between ring members and non-ring members
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applicants ASTELLAS PHARMA INC.
Inventors NAKAJIMA, Yutaka
IMADA, Sunao
YAMAMOTO, Eriko
TSUCHIYA, Kazuyuki
HARAYAMA, Yu
MATSUMOTO, Shunichiro
Priority Data 2017-010321 24.01.2017 JP
Title
(EN) PHENYLDIFLUOROMETHYL-SUBSTITUTED PROLINEAMIDE COMPOUND
Abstract
(EN) [Problem] To provide a compound useful as a cathepsin S inhibitor.[Solution] The present inventors have studied on a compound which has a cathepsin S-inhibiting activity and can be used as an active ingredient for a pharmaceutical composition for preventing and/or treating an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis an allergy or organ bone marrow or tissue graft rejection. As a result it has been confirmed that a phenyldifluoromethyl-substituted prolineamide compound according to the present invention has a cathepsin S-inhibiting activity. This confirmation leads to the accomplishment of the present invention. The phenyldifluoromethyl-substituted prolineamide compound according to the present invention has a cathepsin S-inhibiting activity and can be used as a prophylactic and/or therapeutic agent for an autoimmune disease such as SLE and nephritis an allergy or organ bone marrow or tissue graft rejection.
Related patent documents
UAa201908429This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
JOJOP20190181This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.